Protagonist Therapeutics, Inc. (NASDAQ:PTGX) | WebDisclosure

Basculer en Français

10100	Companies
206853	Keywords
137011	Articles
109639	Press releases

Headlines Articles Press releases Protagonist Therapeutics, Inc.

Home
Companies
Protagonist Therapeutics, Inc.

PRESS RELEASE

published on 05/14/2024 at 22:05, 1 year 10 months ago

Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress
Protagonist Therapeutics to present rusfertide Phase 2 REVIVE study data at EHA Congress in Madrid. Study shows absence of QTc prolongation with rusfertide. Details on pipeline drugs and collaborations available on company's website

Clinical Development Collaborations Protagonist Therapeutics Rusfertide EHA Congress

Accesswire

Published on 03/26/2026 at 23:00, 15 minutes ago

FutureGen Industries Announces Closing of Debt Settlement
Published on 03/26/2026 at 22:05, 1 hour 10 minutes ago

BlackBerry to Announce Fourth Quarter and Fiscal Year 2026 Results on April 9, 2026
Published on 03/26/2026 at 22:00, 1 hour 15 minutes ago

Clean Air Metals Receives Provincial Funding and Provides Update on the Thunder Bay North Project
Published on 03/26/2026 at 22:00, 1 hour 15 minutes ago

Green Bridge Metals Reports Visible Copper Sulfide Mineralization in Initial 2026 Titac Drilling, Duluth Complex Minnesota
Published on 03/26/2026 at 21:00, 2 hours 15 minutes ago

Worksport Reports Record FY 2025 Results, Issues $35M–$42M 2026 Revenue Guidance; Targets Initial Cash Flow Positivity

View all ACCESSWIRE

EQS Group

Published on 03/26/2026 at 20:48, 2 hours 26 minutes ago

Dermapharm Holding SE repurchases 4,299,190 shares under its public share buyback offer
Published on 03/26/2026 at 19:20, 3 hours 54 minutes ago

Critical Path Institute Launches 'One to Millions' to Reshape the Future of Individualized Medicine at Global Scale
Published on 03/26/2026 at 19:13, 4 hours 1 minute ago

Director Declaration
Published on 03/26/2026 at 19:09, 4 hours 5 minutes ago

2CRSi SA: Résultats 1er Semestre 2025/26 : Chiffre d'Affaires 204,7 M€ (x9,8) EBITDA de 9,6 M€ (x4,6)
Published on 03/26/2026 at 19:09, 4 hours 5 minutes ago

2CRSi SA: First Half 2025/26 Results: Revenue of €204.7 million (x9.8) EBITDA of €9.6 million (x4.6)

Les Echos

Published on 03/26/2026 at 18:17, 4 hours 58 minutes ago

Eiffage se renforce au capital de Getlink et porte sa participation à 29,40 % du capital
Published on 03/26/2026 at 18:17, 4 hours 58 minutes ago

Eiffage strengthens its position in Getlink capital
Published on 03/26/2026 at 18:00, 5 hours 15 minutes ago

Arrêté des comptes au 31 décembre 2025 et perspectives 2026
Published on 03/26/2026 at 18:00, 5 hours 15 minutes ago

Calendrier financier 2026
Published on 03/26/2026 at 18:00, 5 hours 15 minutes ago

LABORATOIRES EUROMEDIS - Fin du contrat de liquidité

View all LES ECHOS COMFI WIRE